Haemonetics (HAE) Competitors $77.79 +1.82 (+2.40%) Closing price 07/9/2025 03:57 PM EasternExtended Trading$77.49 -0.30 (-0.39%) As of 08:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HAE vs. DXCM, HQY, LNTH, PODD, QTRX, SIBN, PEN, ZBH, ALGN, and MMSIShould you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), Quanterix (QTRX), SiBone (SIBN), Penumbra (PEN), Zimmer Biomet (ZBH), Align Technology (ALGN), and Merit Medical Systems (MMSI). These companies are all part of the "medical" sector. Haemonetics vs. Its Competitors DexCom HealthEquity Lantheus Insulet Quanterix SiBone Penumbra Zimmer Biomet Align Technology Merit Medical Systems DexCom (NASDAQ:DXCM) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Does the media favor DXCM or HAE? In the previous week, DexCom had 15 more articles in the media than Haemonetics. MarketBeat recorded 22 mentions for DexCom and 7 mentions for Haemonetics. DexCom's average media sentiment score of 1.35 beat Haemonetics' score of 1.27 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, DXCM or HAE? DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDexCom$4.03B8.25$576.20M$1.3463.34Haemonetics$1.36B2.75$167.68M$3.3123.50 Do analysts recommend DXCM or HAE? DexCom presently has a consensus price target of $98.50, suggesting a potential upside of 16.06%. Haemonetics has a consensus price target of $97.30, suggesting a potential upside of 25.08%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95Haemonetics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of DXCM or HAE? 97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 1.8% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, DXCM or HAE? DexCom has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Is DXCM or HAE more profitable? DexCom has a net margin of 12.90% compared to Haemonetics' net margin of 12.32%. DexCom's return on equity of 30.05% beat Haemonetics' return on equity.Company Net Margins Return on Equity Return on Assets DexCom12.90% 30.05% 10.00% Haemonetics 12.32%26.37%9.22% SummaryDexCom beats Haemonetics on 12 of the 17 factors compared between the two stocks. Get Haemonetics News Delivered to You Automatically Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HAE vs. The Competition Export to ExcelMetricHaemoneticsMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.65B$10.41B$5.51B$20.49BDividend YieldN/A2.09%5.25%3.74%P/E Ratio23.5016.4028.0227.90Price / Sales2.7531.20417.6739.35Price / Cash10.5422.7937.0622.25Price / Book4.763.728.144.59Net Income$167.68M$235.43M$3.16B$982.91M7 Day Performance1.23%2.31%3.16%0.11%1 Month Performance7.78%2.59%3.49%3.55%1 Year Performance-10.65%-10.94%34.22%13.79% Haemonetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HAEHaemonetics4.8774 of 5 stars$77.79+2.4%$97.30+25.1%-7.7%$3.65B$1.36B23.503,023News CoveragePositive NewsAnalyst UpgradeGap UpDXCMDexCom4.8727 of 5 stars$87.29+1.1%$98.50+12.8%-23.4%$33.85B$4.03B65.1410,300Positive NewsHQYHealthEquity3.7285 of 5 stars$104.76-0.1%$118.09+12.7%+22.4%$9.07B$1.20B39.733,120Analyst ForecastInsider TradeLNTHLantheus4.4537 of 5 stars$81.86+0.5%$130.50+59.4%+7.5%$5.64B$1.53B14.22700PODDInsulet4.1244 of 5 stars$314.18+0.4%$321.00+2.2%+52.4%$22.03B$2.07B56.513,900Positive NewsAnalyst ForecastQTRXQuanterix2.4893 of 5 stars$6.65flat$15.60+134.6%-53.4%$332.20M$137.42M0.00460SIBNSiBone4.031 of 5 stars$18.82+2.1%$22.50+19.6%+37.1%$785.39M$167.18M0.00350News CoveragePositive NewsPENPenumbra4.8352 of 5 stars$256.00-0.2%$302.40+18.1%+37.1%$9.93B$1.19B77.944,500Analyst ForecastZBHZimmer Biomet4.9257 of 5 stars$91.23-0.3%$111.53+22.2%-10.0%$18.10B$7.68B11.6217,000Positive NewsAnalyst ForecastALGNAlign Technology4.5377 of 5 stars$189.33+0.4%$241.25+27.4%-19.0%$13.66B$4.00B34.4920,945Positive NewsAnalyst ForecastMMSIMerit Medical Systems4.392 of 5 stars$93.480.0%$109.11+16.7%+11.7%$5.53B$1.36B45.827,400Analyst Forecast Related Companies and Tools Related Companies DexCom Alternatives HealthEquity Alternatives Lantheus Alternatives Insulet Alternatives Quanterix Alternatives SiBone Alternatives Penumbra Alternatives Zimmer Biomet Alternatives Align Technology Alternatives Merit Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HAE) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
